Читать книгу Complementary and Alternative Medicine (CAM) Supplement Use in People with Diabetes: A Clinician's Guide - Laura Shane-McWhorter - Страница 22

Gymnema has been researched since the 1930s.⁶⁸ In a study of 27 patients with type 1 diabetes, gymnema was administered at a dose of 200 mg twice a day for 6–30 months.⁶⁹ The researchers tracked A1C, fasting blood glucose, and insulin dose. Average A1C declined from 12.8% at baseline to 9.5% after 6–8 months (P < 0.001), and after 16–18 months 22 individuals continuing to take gymnema had a mean A1C of 9% (P values not stated). At the end of 26–30 months, six patients remaining on gymnema had a further decline to 8.2% (P values not stated). Average fasting glucose declined from 232 mg/dl (12.9 mmol/l) at baseline to 177 mg/dl (9.8 mmol/l) after 6–8 months, 150 mg/dl (8.2 mmol/l) after 16–18 months, and 152 mg/dl (8.4 mmol/l) after 20–24 months (P values not stated). Average insulin dose decreased from 60 units/day to 45 units/day after 6–8 months and declined further to 30 units/day after 26–30 months (P values not stated). A control group of 37 patients who took only insulin was also followed for 10–12 months, and these individuals had no change in blood glucose or A1C.

In a different study, 22 patients with type 2 diabetes took gymnema at a dose of 400 mg daily for 18–20 months in addition to a sufonylurea.⁷⁴ A1C declined from an average baseline of 11.9% to 8.5% (P < 0.001), and average fasting glucose decreased from 174 mg/dl (9.7 mmol/l) at baseline to 124 mg/dl (6.9 mmol/l) after 18–20 months (P < 0.001). Notably, five individuals were able to discontinue sulfonylurea treatment. Lipids also significantly declined in this study. A control group of 25 patients on sulfonylureas plus placebo had no significant changes in A1C, fasting glucose, or lipids.